Korean J Perinatol.  2011 Mar;22(1):57-63.

The Therapeutic Effect of Inhaled Iloprost in Newborn Infants with Severe Persistent Pulmonary Hypertension Refractory to Inhaled Nitric Oxide

Affiliations
  • 1Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea. ranng@yuhs.ac

Abstract

Inhaled iloprost, a stable carbacyline derivative of prostacyclin, has been used recently for the treatment of adults with pulmonary hypertension but only few reports are available about its use in neonatal critical care. We report therapeutic trial of inhaled iloprost in newborn infants with persistent pulmonary hypertension of the newborn (PPHN) who did not respond to inhaled nitric oxide (iNO). Inhaled iloprost (Ventavis(R), Bayer Shering Pharma, Germany) was effective in neonates with severe PPHN who showed inadequate response to iNO. We suggest that inhaled iloprost could be considered as an additional therapeutic option in PPHN refractory to iNO.

Keyword

Iloprost; Persistent pulmonary hypertension of the newborn; Nitric oxide

MeSH Terms

Adult
Critical Care
Epoprostenol
Humans
Hypertension, Pulmonary
Iloprost
Infant, Newborn
Nitric Oxide
Epoprostenol
Iloprost
Nitric Oxide
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr